Results 41 to 50 of about 249 (106)

Modern view on anti-inflammatory and urat-lowering therapy for gout

, 2023
У статті наводиться огляд нових та перспективних препаратів для протизапальної та уратзнижувальної терапії подагри – як уже зареєстрованих та застосовуваних у клінічній практиці, так і тих що знаходяться на етапах впровадження або клінічного дослідження ...
Бабаніна, Марина Юріївна, Кир'ян, Олена Анатоліївна, Babanina, M. Yu., Volchenko, H. V., Волченко, Григорій Вілійович, Kyryan, O. A., Kitura, Ye. M., Ткаченко, Максим Васильович, Кітура, Євдокія Михайлівна, Tkachenko, M. V.   +9 more
core   +1 more source

Benzofuran‐Based Uricosuric Agents: History, Roles, and Challenges

ChemistrySelect, Volume 11, Issue 24, 25 June 2026.
Benzofuran‐based uricosuric agents represent a privileged medicinal chemistry scaffold for gout therapy. Structural optimization of benzbromarone‐related derivatives has improved hURAT1 inhibitory potency, metabolic stability, and urate‐lowering efficacy, while reducing hepatotoxic liability.
Raed M. Al‐Zoubi, Basma Hanbali, Mai Elaarag, Zainab Fares, Enas A. Al‐Hurani, Sally R. Al‐Zoubi, Mohanad Shkoor, Abdelali Agouni   +7 more
wiley   +1 more source

Exploring a Subpopulation of MASLD Associated With New Onset of CKD Using Supervised Clustering Techniques

Hepatology Research, Volume 56, Issue 5, Page 762-777, May 2026.
The supervised clustering of metabolic dysfunction‐associated steatotic liver disease (MASLD) using a SHapley Additive exPlanations (SHAP)‐converted matrix reveals distinct subpopulations that improved risk stratification for new onset of chronic kidney disease (CKD).
Itaru Hosaka, Marenao Tanaka, Tatsuya Sato, Yukinori Akiyama, Keitaro Nishizawa, Rie Matsumori, Hiroki Aida, Wataru Kawaharata, Kei Nakata, Koki Abe, Toru Suzuki, Hidemichi Kouzu, Naoya Yama, Nagisa Hanawa, Masato Furuhashi   +14 more
wiley   +1 more source

Six‐Year Trends in Real‐World Data Use for Post‐Marketing Surveillance of New Medical Products in Japan

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT The Ministerial Ordinance on Good Post‐Marketing Study Practice for Drugs was amended by the Ministry of Health, Labour and Welfare (MHLW) in 2018 to clearly define post‐marketing database studies (DBS) as a measure of pharmacovigilance activities for approved medical products in Japan.
Suguru Okami, Kako Shimotsumagari, Yasunari Sadatsuki   +2 more
wiley   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: Transporters

British Journal of Pharmacology, Volume 182, Issue S1, Page S404-S496, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Chloe J. Peach, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Laura Amarosi, Catriona M. H. Anderson, Philip M. Beart, Stefan Broer, Paul A. Dawson, Gergely Gyimesi, Bruno Hagenbuch, James R. Hammond, Jules C. Hancox, Michal Hershfinkel, Ken‐ichi Inui, Yoshikatsu Kanai, Stephan Kemp, Edmund R. S. Kunji, Gavin Stewart, Sotiria Tavoulari, David T. Thwaites, Tiziano Verri   +28 more
wiley   +1 more source

2024 Update of Chinese Guidelines for Management of Hyperuricemia and Gout Part II: Recommendations for Patients With Common Comorbidities

International Journal of Rheumatic Diseases, Volume 28, Issue 8, August 2025.
ABSTRACT Objective The aim of this updated guideline is to provide comprehensive recommendations for the management of gout in patients with common comorbidities, such as chronic kidney disease (CKD), cardiovascular disease (CVD), diabetes, osteoarthritis (OA), and gastrointestinal disorders.
Changgui Li, Mingshu Sun, Zhen Liu, Detian Li, Changqian Wang, Zibin Tian, Yuxiang Dai, Zhe Feng, Chengfu Xu, Dongbao Zhao, Feng Wei, Bo Ban, Chao Xie, Zhenmei An, Jia Liu, Zhuo Li, Yuwei He, Xinde Li, Fei Yan, Lin Han, Lidan Ma, Xiaoyu Cheng, Tian Liu, Xufei Luo, Lingling Cui, Ying Gong, Can Wang, Yaolong Chen, Zhaohui Lyu, Ronald M. L. Yip, Jiajun Zhao   +30 more
wiley   +1 more source

Metabolomic and Cellular Mechanisms of Drug‐Induced Ototoxicity and Nephrotoxicity: Therapeutic Implications of Uric Acid Modulation

Advanced Science, Volume 12, Issue 16, April 24, 2025.
Drug‐induced renal damage impairs uric acid excretion, causing its accumulation in the serum, which subsequently infiltrates the cochlea. Xanthine oxidase and the ABCG2 transporter, critical in uric acid metabolism and excretion, undergo pathological changes in renal tubular and cochlear stria vascularis cells.
Suhan Guo, Cheng Cheng, Yunhao Wu, Kaidi Shen, Depeng Zhang, Bin Chen, Xinyu Wang, Luping Shen, Qixiang Zhang, Renjie Chai, Guangji Wang, Fang Zhou   +11 more
wiley   +1 more source

Association of xanthine oxidoreductase inhibitor use with insulin secretory capacity in patients with type 2 diabetes

Journal of Diabetes Investigation, Volume 15, Issue 10, Page 1500-1509, October 2024.
XOR inhibitor treatment was examined for its effects on insulin secretory capacity. XOR inhibitor use was positively associated with CPR and CPI in 428 patients with type 2 diabetes. XOR inhibition may provide protection of insulin secretory capacity in such patients.
Atsushi Kitamura, Masafumi Kurajoh, Yuya Miki, Yoshinori Kakutani, Yuko Yamazaki, Akinobu Ochi, Tomoaki Morioka, Katsuhito Mori, Tetsuo Shoji, Masanori Emoto   +9 more
wiley   +1 more source

Additional file 5 of Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)

, 2023
Additional file 5: Table S4.
Isao Taguchi (3472403), Itaru Hisauchi (16560137), Toshiaki Kadokami (3472397), Hiroshi Hongo (3026754), Tetsuya Ishikawa (653995), Shusuke Yagi (220199), Hisako Yoshida (685101), Michio Shimabukuro (656310), Koichi Node (384063), Masataka Sata (327827), Atsushi Tanaka (40313)   +10 more
core   +1 more source

Switching from febuxostat to dotinurad in patients with chronic kidney disease and hyperuricemia: a single-center, non-randomized study

Recently, an observational study demonstrated that a lower fractional excretion of uric acid (FEUA) is significantly associated with a higher risk of kidney failure. This study aimed to assess the efficacy of switching from febuxostat to dotinurad, which
Shigeharu Kashiwado, Taisuke Irifuku, Takao Masaki   +2 more
core   +1 more source